Neurocrine Biosciences, Inc. (NBIX) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, everyone, and welcome to today's Neurocrine Biosciences third quarter 2025 results call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing star 1 on your telephone keypad. Please note this call is being recorded. I will be standing by if you should need any assistance. It is now my pleasure to turn the conference over to Vice President of Investor Relations, Todd Tushla. Hi, everybody, and a very pleasant good afternoon to you, wherever you may be. Welcome to Neurocurrent Biosciences' third quarter 2025 earnings call. I'm joined today by Kyle Gaino, Chief Executive Officer, Matt Abernathy, Chief Financial Officer, Eric Benevich, Chief Commercial Officer, and Sanjay Kaswani, Chief Medical Officer. During our call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. After prepared remarks and as is our standard practice, we will try to address all your questions. With that, I turn the call over to Kyle. Thank you, Todd. Good afternoon, everyone. Our third quarter results reflect Neurocrin's exceptional execution and the strength of our enterprise-wide momentum as we continue to deliver across our commercial, clinical, and operational objectives. From a commercial perspective, for Ingresa, the recent investments to expand our sales force and improve patient access drove yet another record quarter for both new patient starts and total prescriptions, highlighting the persistent unmet need for patients with tardive dyskines...